ABSTRACT
Objective To study the clinicopathological significance of the expression of glutameta decarboxylase 65(GDA65) and protein kinase C(PKC) in the central cancer tissues, cancer edge tissues, paracancerous liver tissue and non-cancer liver tissues. Methods The expression of GDA65 and PKC were detected by immunohistochemical method in 10% neutral formalin- fixed and routinely paraffin-embedded sections in 37 hepatic cancer specimen. Results The positive rate and the score of GDA65 and PKC in the cancer tissues were significantly higher than that in the paracancer tissues or non-cancer liver tissues, but the PKC expression was no difference between the central cancer tissues and the cancer edge tissues . The expression of GDA 65 was related to the pathological types, differentiated degrees, liver cirrhosis or metastasis of hepatocarcinomas. No correlation was found between the expression of PKC and the clinicopathological features of hepatocarcinomas. Conclusions The expression of GDA65 and PKC might be closely related to the carcinogenesis of hepatocarcinoma, they might be important biological markers of hepatocarcinoma.
ABSTRACT
Objective To detect the inhibitory effect of HSP27-siRNA on hepatocellular carcinoma(HCC) cells.Methods HCC cell QGY lines were cultured with HSP27-siRNA in a differtent range of concentration for various time periods.Cell activity was studied by MTT.The changes of cell cycle and apoptosis were analyzed by FCM.RT-PCR was used to detect the effect of HSP27-siRNA on QGY cell expression of HSP27 mRNA.Western blot was used to detect the inhibition efficiency of HSP27-siRNA on HSP27protein.Results The proliferation of QGY cell was inhibited by HSP27-siRNA,and HSP27-siRNA decreased the expression of HSP27 protein.HSP27-siRNA inhibited the proliferation of QGY cell line and induced apoptosis in vitro,and its effect was both dose-and time-dependent.Conclusions HSP27-siRNA can inhibit proliferation and induce apoptosis of HCC cancer cell lines.Thus,it may become a method for effective treatment of HCC cancer.